LENSAR, Inc. (LNSR) presents a deeply negative liquidation posture under the standard balance-sheet liquidation framework. Total assets per XBRL are $66.2M against total liabilities of $41.6M, yielding book equity of $10.8M. However, applying liquidation haircuts collapses recovery to equity rapidly. Cash of $12.5M recovers at 100%. Net AR of $4.9M recovers at approximately $4.4-4.7M (90-95%). The single largest asset by book value is inventory at $23.1M (raw materials $18.9M, WIP $1.3M, finished goods $2.9M); at a 60% recovery rate this yields approximately $13.9M. PP&E net is negligible at $457K, recovering perhaps $230-320K. Intangible assets net $5.0M (gross $14.1M, accumulated amortization $9.1M) recover at zero under the liquidation lens. Other non-current assets of $2.6M include notes receivable and other items that would recover at a steep discount or zero. The LENSAR brand name intangible is carried at an indefinite life and would receive zero recovery. Total gross recoverable asset value approximates $35-37M before considering liability settlement. On the liability side, face-value obligations include total current liabilities of $17.8M (accounts payable $10.1M, accrued liabilities $3.9M, deferred revenue $3.0M, operating lease current $785K, other), non-current liabilities of approximately $23.8M inclusive of the Series A Redeemable Convertible Preferred Stock carried in temporary equity at $13.8M with a liquidation preference of $20.0M, a $5.0M long-term note payable, operating lease non-current $1.8M, and other non-current liabilities $815K. The Series A preferred ranks senior to common in liquidation with a $20M liquidation preference, which directly reduces any common equity recovery. Netting estimated liquidated assets of approximately $35-37M against face-value liabilities including the preferred's $20M liquidation preference and $21.6M in total debt and other obligations leaves common equity recovery near zero or negative. This is consistent with MFFAIS CLV of negative $7.1M for common equity. The termination of the Alcon merger agreement in March 2026 (referenced in the exhibit list) removes a prior strategic premium and brings LENSAR back to standalone operating/liquidation dynamics. The $36.3M GAAP net income for Q1 2026 is predominantly driven by a $23.9M non-cash gain from fair value adjustment of warrants and the $12.8M acquisition-related termination fee received from Alcon upon deal termination — both one-time, non-recurring items with zero liquidation value. Operating cash flow for Q1 2026 was negative $4.3M, confirming the company consumes cash on a standalone basis. Federal NOL carryforwards of $52.6M as of December 31, 2025 carry zero liquidation value given a full valuation allowance. The filing does not separately disclose the valuation allowance amount in XBRL tags provided, but the zero income tax expense line confirms no tax benefit is recognized. The massive inventory balance ($23.1M, predominantly raw materials at $18.9M) relative to trailing revenue (~$13.4M for Q1 2026) raises concentration risk on liquidation recovery; medical device components are specialized and may not realize even 60% without a strategic buyer.
▼ Community Notes